Gene therapy in corneal transplantation

Area of Science:

• Ophthalmology and immunology
• Transplantation science
• Gene therapy applications

Background:

• Corneal transplantation is the most frequent organ transplant, with high success rates in low-risk settings.
• Immune rejection remains the primary cause of corneal graft failure, especially in high-risk patients.
• Current corticosteroid treatments for rejection have limitations, including side effects and short action duration.

Purpose of the Study:

• To review the progress of gene therapy in enhancing corneal graft survival.
• To explore gene-mediated strategies for preventing allogeneic graft rejection.
• To discuss future directions for ocular gene therapy in transplantation.

Main Methods:

• Review of current literature on gene therapy techniques for ocular transplantation.
• Discussion of viral vectors and alternative splicing in gene delivery.
• Analysis of experimental approaches for immunomodulation in corneal grafts.

Main Results:

• Gene therapy presents a novel approach to overcome limitations of current immunosuppressive treatments.
• Various gene therapy strategies are being investigated for their potential to promote graft survival.
• Progress has been made in developing efficient viral vectors for ocular gene delivery.

Conclusions:

• Experimental ocular gene therapy holds significant promise for improving corneal graft survival.
• Targeted, gene-mediated prevention of rejection could offer a more sustainable solution than corticosteroids.
• Further research into gene therapy is crucial for advancing corneal transplantation outcomes.